Programmed Cell Death Ligand 1-Inhibiting MicroRNAs in Hepatocellular Carcinoma: A Systematic Review PDL1-inhibiting miRs in hepatocellular carcinoma
Trends in Peptide and Protein Sciences,
Vol. 8 No. 1 (2023),
4 November 2023
,
Page 1-14 (e1)
https://doi.org/10.22037/tpps.v8i1.40738
Abstract
The Programmed cell death ligand-1 (PD-L1), an immune checkpoint molecule, is the ligand of Programmed cell death protein 1 (PD-1). They are crucial molecules in maintaining immune homeostasis. PD-L1/PD-1 axis regulates the initiation and maintenance of tolerance and protects tissues from autoimmune responses; however, cancer cells can use the PD-1/PD-1 axis to evade the anti-tumor response of immune cells. Increased PD-L1 expression is directly associated with poor prognosis in hepatocellular carcinoma (HCC). Although immunotherapy with immune checkpoint inhibitors (ICIs) are leading therapy in cancer treatment, using biomarkers to regulate immune checkpoints at the RNA level is considered a promising tool in novel therapeutic approaches. Increasing evidence has reported that miRNAs are critical regulators of tumor development. Hence, we performed a current systematic review to explore PD-L1 inhibiting miRNAs involved in hepatocellular carcinoma. Five databases were systemically searched to obtain the relevant original articles. Consequently, seventeen studies were included in the current systematic review. According to obtained literatures, some microRNAs, namely miR-194-5p, -675-5p, 194-5p, -1, -455-5p, -223-3p, -513, -195, -506, -329-3p, -424, -411-5p, -182-5p, -200, -378a-3p, -570, -200c, and -513a-5p can inhibit PD-L1 expression in HCC cells. These can ultimately reduce tumor proliferation, inhibit tumor migration, stimulate the chemosensitivity of cancer cells, and induce apoptosis in tumor cells. Moreover, the investigated miRNAs were further analyzed using miRNA target prediction online tools to highlight the future direction of their functions in HCC.
HIGHLIGHTS
- Cancer cells can use the PD-1/PD-1 axis to evade the anti-tumor response of immune cells.
- Increased PD-L1 expression is directly associated with poor prognosis in hepatocellular carcinoma.
- Several microRNAscan inhibit PD-L1 expression in HCC cells.
- Hepatocellular carcinoma (HCC)
- In silico study
- MicroRNA
- Programmed death-ligand 1 (PD-L1)
How to Cite
References
Ali Syeda, Z., S. S. S. Langden, C. Munkhzul, M. Lee and S. J. Song, (2020). "Regulatory mechanism of microRNA expression in cancer." International Journal of Molecular Sciences, 21(5): 1723. DOI: https://doi.org/10.3390/ijms21051723.
Bao, C., Y. Li, L. Huan, Y. Zhang, F. Zhao, Q. Wang, L. Liang, J. Ding, L. Liu and T. Chen, (2015). "NF-κB signaling relieves negative regulation by miR-194 in hepatocellular carcinoma by suppressing the transcription factor HNF-1α." Science Signaling, 8(387): ra75-ra75. DOI: https://doi.org/10.1126/scisignal.aaa8441.
Bray, F., J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre and A. Jemal, (2018). "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries." CA: A Cancer Journal for Clinicians, 68(6): 394-424. DOI: https://doi.org/10.3322/caac.21492.
Calderaro, J., B. Rousseau, G. Amaddeo, M. Mercey, C. Charpy, C. Costentin, A. Luciani, E. S. Zafrani, A. Laurent and D. Azoulay, (2016). "Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features." Hepatology, 64(6): 2038-2046. DOI: https://doi.org/10.1002/hep.28710.
Cao, M.-Q., A.-B. You, X.-D. Zhu, W. Zhang, Y.-Y. Zhang, S.-Z. Zhang, K.-w. Zhang, H. Cai, W.-K. Shi and X.-L. Li, (2018). "miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a." Journal of Hematology and Oncology, 11(1): 1-12. DOI: https://doi.org/10.1186/s13045-018-0555-y.
Cao, X., G. Zhang, T. Li, C. Zhou, L. Bai, J. Zhao and T. Tursun, (2020). "LINC00657 knockdown suppresses hepatocellular carcinoma progression by sponging miR-424 to regulate PD-L1 expression." Genes and Genomics, 42(11): 1361-1368. DOI: https://doi.org/10.1007/s13258-020-01001-y.
Chen, L., D. L. Gibbons, S. Goswami, M. A. Cortez, Y.-H. Ahn, L. A. Byers, X. Zhang, X. Yi, D. Dwyer and W. Lin, (2014). "Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression." Nature Communications, 5(1): 1-12. DOI: https://doi.org/10.1038/ncomms6241.
Chen, T., R. Liu, Y. Niu, H. Mo, H. Wang, Y. Lu, L. Wang, L. Sun, Y. Wang and K. Tu, (2021). "HIF-1α-activated long non-coding RNA KDM4A-AS1 promotes hepatocellular carcinoma progression via the miR-411-5p/KPNA2/AKT pathway." Cell Death and Disease, 12(12): 1-12. DOI: https://doi.org/10.1038/s41419-021-04449-2.
Dai, W., H. L. Huang, M. Hu, S.-J. Wang, H. J. He, N. P. Chen and M. Y. Li, (2015). "microRNA-506 regulates proliferation, migration and invasion in hepatocellular carcinoma by targeting F-spondin 1 (SPON1)." American Journal of Cancer Research, 5(9): 2697. PMID: 26609477.
Dai, X., G. Pi, S. L. Yang, G. G. Chen, L. P. Liu and H. H. Dong, (2018). "Association of PD-L1 and HIF-1α coexpression with poor prognosis in hepatocellular carcinoma." Translational Oncology, 11(2): 559-566. DOI: https://doi.org/10.1016/j.tranon.2018.02.014.
Deng, Q., L. Xie and H. Li, (2015). "MiR-506 suppresses cell proliferation and tumor growth by targeting Rho-associated protein kinase 1 in hepatocellular carcinoma." Biochemical and Biophysical Research Communications, 467(4): 921-927. DOI: https://doi.org/10.1016/j.bbrc.2015.10.043.
Dong, Z., R. Qi, X. Guo, X. Zhao, Y. Li, Z. Zeng, W. Bai, X. Chang, L. Hao and Y. Chen, (2017). "MiR-223 modulates hepatocellular carcinoma cell proliferation through promoting apoptosis via the Rab1-mediated mTOR activation." Biochemical and Biophysical Research Communications, 483(1): 630-637. DOI: https://doi.org/10.1016/j.bbrc.2016.12.091.
Fan, F., K. Chen, X. Lu, A. Li, C. Liu and B. Wu, (2021). "Dual targeting of PD-L1 and PD-L2 by PCED1B-AS1 via sponging hsa-miR-194-5p induces immunosuppression in hepatocellular carcinoma." Hepatology International, 15(2): 444-458. DOI: https://doi.org/10.1007/s12072-020-10101-6.
Feng, J., J. Wang, M. Chen, G. Chen, Z. Wu, L. Ying, Q. Zhuo, J. Zhang and W. Wang, (2015). "miR-200a suppresses cell growth and migration by targeting MACC1 and predicts prognosis in hepatocellular carcinoma." Oncology Reports, 33(2): 713-720. DOI: https://doi.org/10.3892/or.2014.3642.
Gao, Q., X. Y. Wang, S. J. Qiu, I. Yamato, M. Sho, Y. Nakajima, J. Zhou, B. Z. Li, Y. H. Shi and Y. S. Xiao, (2009). "Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma." Clinical Cancer Research, 15(3): 971-979. DOI: https://doi.org/10.1158/1078-0432.CCR-08-1608.
Guangshun, S., S. Guoqiang, C. Xin, K. Xiangyi, Z. Wubin, L. Zhitao, Z. Zhiying, C. Hongyong, L. Chengyu and X. Yongxiang, (2022). "Meloxicam Inhibits Hepatocellular Carcinoma Progression and Enhances the Sensitivity of Immunotherapy via the MicroRNA-200/PD-L1 Pathway." Journal of Oncology, 2022: 4598573. DOI: https://doi.org/10.1155/2022/4598573.
Guo, W., W. Tan, S. Liu, X. H. Huang, J. Z. Lin, R. H. Liang, L. Su, Q. Su and C. J. Wang, (2015). "miR-570 inhibited the cell proliferation and invasion through directly targeting B7-H1 in hepatocellular carcinoma." Tumor Biology, 36(11): 9049-9057. DOI: https://doi.org/10.1007/s13277-015-3644-3.
Hammond, S. M. (2015). "An overview of microRNAs." Advanced Drug Delivery Reviews, 87: 3-14. DOI: https://doi.org/10.1016/j.addr.2015.05.001.
Hu, Y., Z. Yang, D. Bao, J.-S. Ni and J. Lou, (2019). "miR-455-5p suppresses hepatocellular carcinoma cell growth and invasion via IGF-1R/AKT/GLUT1 pathway by targeting IGF-1R." Pathology-Research and Practice, 215(12): 152674. DOI: https://doi.org/10.1016/j.prp.2019.152674.
Huang, H. Y., Y. C. D. Lin, J. Li, K. Y. Huang, S. Shrestha, H. C. Hong, Y. Tang, Y. G. Chen, C. N. Jin and Y. Yu, (2020). "miRTarBase 2020: updates to the experimentally validated microRNA–target interaction database." Nucleic Acids Research 48(D1): D148-D154. DOI: https://doi.org/10.1093/nar/gkz896.
Hutvagner, G. and P. D. Zamore, (2002). "A microRNA in a multiple-turnover RNAi enzyme complex." Science, 297(5589): 2056-2060. DOI: https://doi.org/10.1126/science.1073827.
Janowski, B. A., S. T. Younger, D. B. Hardy, R. Ram, K. E. Huffman and D. R. Corey, (2007). "Activating gene expression in mammalian cells with promoter-targeted duplex RNAs." Nature Chemical Biology, 3(3): 166-173. DOI: https://doi.org/10.1038/nchembio860.
Ji, Y., S. Yang, X. Yan, L. Zhu, W. Yang, X. Yang, F. Yu, L. Shi, X. Zhu and Y. Lu, (2021). "CircCRIM1 promotes hepatocellular carcinoma proliferation and angiogenesis by sponging miR-378a-3p and regulating SKP2 expression." Frontiers in Cell and Developmental Biology, 9. DOI: https://doi.org/10.3389/fcell.2021.796686.
Jung, H. I., D. Jeong, S. Ji, T. S. Ahn, S. H. Bae, S. Chin, J. C. Chung, H. C. Kim, M. S. Lee and M. J. Baek, (2017). "Overexpression of PD-L1 and PD-L2 is associated with poor prognosis in patients with hepatocellular carcinoma." Cancer Research and Treatment, 49(1): 246-254. DOI: https://doi.org/10.4143/crt.2016.066.
Khare, S., Q. Zhang and J. A. Ibdah, (2013). "Epigenetics of hepatocellular carcinoma: role of microRNA." World Journal of Gastroenterology: WJG, 19(33): 5439. DOI: https://doi.org/10.3748/wjg.v19.i33.5439.
Khraiwesh, B., M. A. Arif, G. I. Seumel, S. Ossowski, D. Weigel, R. Reski and W. Frank, (2010). "Transcriptional control of gene expression by microRNAs." Cell, 140(1): 111-122. DOI: https://doi.org/10.1016/j.cell.2009.12.023.
Kong, X., Z. Zheng, G. Song, Z. Zhang, H. Liu, J. Kang, G. Sun, G. Sun, T. Huang and X. Li, (2022). "Over-expression of GUSB leads to primary resistance of anti-PD1 therapy in hepatocellular carcinoma." Frontiers in Immunology, 13. DOI: https://doi.org/10.3389/fimmu.2022.876048.
Kozomara, A., M. Birgaoanu and S. Griffiths-Jones, (2019). "miRBase: from microRNA sequences to function." Nucleic Acids Research, 47(D1): D155-D162. DOI: https://doi.org/10.1093/nar/gky1141.
Kuleshov, M. V., M. R. Jones, A. D. Rouillard, N. F. Fernandez, Q. Duan, Z. Wang, S. Koplev, S. L. Jenkins, K. M. Jagodnik and A. Lachmann, (2016). "Enrichr: a comprehensive gene set enrichment analysis web server 2016 update." Nucleic Acids Research, 44(W1): W90-W97. DOI: https://doi.org/10.1093/nar/gkw377.
Lafaro, K. J., A. N. Demirjian and T. M. Pawlik, (2015). "Epidemiology of hepatocellular carcinoma." Surgical Oncology Clinics, 24(1): 1-17. DOI:https://doi.org/10.1016/j.soc.2014.09.001.
Lee, R. C., R. L. Feinbaum and V. Ambros, (1993). "The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14." Cell, 75(5): 843-854. DOI: https://doi.org/10.1016/0092-8674(93)90529-Y.
Li, D., F.F. Sun, D. Wang, T. Wang, J. J. Peng, J.-Q. Feng, H. Li, C. Wang, D. j. Zhou and H. Luo, (2020). "Programmed death ligand-1 (PD-L1) regulated by NRF-2/MicroRNA-1 regulatory axis enhances drug resistance and promotes tumorigenic properties in sorafenib-resistant hepatoma cells." Oncology Research, 28(5): 467-481. DOI: https://doi.org/10.3727/096504020X15925659763817.
Li, D., F. F. Sun, D. Wang, T. Wang, J. J. Peng, J. Q. Feng, H. Li, C. Wang, D. J. Zhou, H. Luo, Z. Q. Fu and T. Zhang (2021). "Erratum: Programmed death ligand-1 (PD-L1) regulated by NRF-2/MicroRNA-1 regulatory axis enhances drug resistance and promotes tumorigenic properties in sorafenib-resistant hepatoma cells." Oncology Research, 28(7): 827-828. DOI: https://doi.org/10.3727/096504021X16280937554409
Li, S., Z. Chen, R. Zhou, S. Wang, W. Wang, D. Liu, M. Li and T. Guo, (2022a). "Hsa_circ_0048674 facilitates hepatocellular carcinoma progression and natural killer cell exhaustion depending on the regulation of miR-223-3p/PDL1." Histology and Histopathology, 37(12):1185-1199. DOI: https://doi.org/10.14670/HH-18-440.
Li, Y., T. Zhou, X. Cheng, D. Li, M. Zhao and W. V. Zheng, (2022b). "microRNA-378a-3p regulates the progression of hepatocellular carcinoma by regulating PD-L1 and STAT3." Bioengineered, 13(3): 4730-4743. DOI: https://doi.org/10.1080/21655979.2022.2031408.
Lin, Y., S. Liu, L. Su, Q. Su, J. Lin, X. Huang and C. Wang, (2018). "miR-570 inhibits proliferation, angiogenesis, and immune escape of hepatocellular carcinoma." Cancer Biotherapy and Radiopharmaceuticals, 33(6): 252-257. DOI: https://doi.org/10.1089/cbr.2017.2389.
Liu, H., L. Xue, C. Song, F. Liu, T. Jiang and X. Yang, (2018). "Overexpression of circular RNA circ_001569 indicates poor prognosis in hepatocellular carcinoma and promotes cell growth and metastasis by sponging miR-411-5p and miR-432-5p." Biochemical and Biophysical Research Communications, 503(4): 2659-2665. DOI: https://doi.org/10.1016/j.bbrc.2018.08.020.
Liu, J., Y. Liu, L. Meng, K. Liu and B. Ji, (2017). "Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma." Oncology Reports, 38(2): 899-907. DOI: https://doi.org/10.3892/or.2017.5722.
Liu, Z., F. Ning, Y. Cai, H. Sheng, R. Zheng, X. Yin, Z. Lu, L. Su, X. Chen and C. Zeng, (2021). "The EGFR‐P38 MAPK axis up‐regulates PD‐L1 through miR‐675‐5p and down‐regulates HLA‐ABC via hexokinase‐2 in hepatocellular carcinoma cells." Cancer Communications, 41(1): 62-78. DOI: https://doi.org/10.1002/cac2.12117.
Mocan, T., Z. Sparchez, R. Craciun, C. Bora and D. Leucuta, (2019). "Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives." Clinical and Translational Oncology, 21(6): 702-712. DOI: https://doi.org/10.1007/s12094-018-1975-4.
Moher, D., A. Liberati, J. Tetzlaff, D. G. Altman and P. G. The, (2009). "Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement." PLOS Medicine, 6(7): e1000097. DOI: https://doi.org/10.7326/0003-4819-151-4-200908180-00135.
Ng, J. and J. Wu, (2012). "Hepatitis B-and hepatitis C-related hepatocellular carcinomas in the United States: similarities and differences." Hepatitis Monthly, 12(10 HCC): e7635. DOI: https://doi.org/10.5812/hepatmon.7635.
Pratama, M. Y., D. Pascut, M. N. Massi and C. Tiribelli, (2019). "The role of microRNA in the resistance to treatment of hepatocellular carcinoma." Annals of Translational Medicine, 7(20): 577. DOI: https://doi.org/10.21037/atm.2019.09.142.
Samir, A., R. A. Tawab and H. M. El Tayebi, (2021). "Long non‑coding RNAs XIST and MALAT1 hijack the PD‑L1 regulatory signaling pathway in breast cancer subtypes." Oncology Letters, 22(2): 1-12. DOI: https://doi.org/10.3892/ol.2021.12854.
Shannon, P., A. Markiel, O. Ozier, N. S. Baliga, J. T. Wang, D. Ramage, N. Amin, B. Schwikowski and T. Ideker, (2003). "Cytoscape: a software environment for integrated models of biomolecular interaction networks." Genome Research, 13(11): 2498-2504. DOI: https://doi.org/10.1101/gr.1239303.
Shi, F., M. Shi, Z. Zeng, R. Z. Qi, Z. W. Liu, J. Y. Zhang, Y. P. Yang, P. Tien and F. S. Wang, (2011). "PD‐1 and PD‐L1 upregulation promotes CD8+ T‐cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients." International Journal of Cancer, 128(4): 887-896. DOI: https://doi.org/10.1002/ijc.25397.
Shrestha, R., P. Prithviraj, M. Anaka, K. R. Bridle, D. H. Crawford, B. Dhungel, J. C. Steel and A. Jayachandran, (2018). "Monitoring immune checkpoint regulators as predictive biomarkers in hepatocellular carcinoma." Frontiers in Oncology, 8: 269. DOI: https://doi.org/10.3389/fonc.2018.00269.
Si, H., H. Wang, H. Xiao, Y. Fang and Z. Wu, (2021). "Anti-tumor effect of celastrol on hepatocellular carcinoma by the circ_SLIT3/miR-223-3p/CXCR4 axis." Cancer Management and Research, 13: 1099. DOI: https://doi.org/10.2147/CMAR.S278023.
Sidhu, K., N. R. Kapoor, V. Pandey and V. Kumar, (2015). "The “macro” world of microRNAs in hepatocellular carcinoma." Frontiers in Oncology, 5: 68. DOI: https://doi.org/10.3389/fonc.2015.00068
Sticht, C., C. De La Torre, A. Parveen and N. Gretz, (2018). "miRWalk: an online resource for prediction of microRNA binding sites." PloS One, 13(10): e0206239. DOI: https://doi.org/10.1371/journal.pone.0206239.
Su, X., J. Su, H. He, Y. Zhan and H. Liu, (2019). "Hsa_circ_0070269 inhibits hepatocellular carcinoma progression through modulating miR-182/NPTX1 axis." Biomedicine and Pharmacotherapy, 120: 109497. DOI: https://doi.org/10.1016/j.biopha.2019.109497.
Sun, C., P. Lan, Q. Han, M. Huang, Z. Zhang, G. Xu, J. Song, J. Wang, H. Wei and J. Zhang, (2018). "Oncofetal gene SALL4 reactivation by hepatitis B virus counteracts miR-200c in PD-L1-induced T cell exhaustion." Nature Communications, 9(1): 1-17. DOI: https://doi.org/10.1038/s41467-018-03584-3.
Sun, G., G. Miao, Z. Li, W. Zheng, C. Zhou, G. Sun, H. Cao, Z. Li and W. Tang, (2022). "Inhibition of PARP potentiates immune checkpoint therapy through miR-513/PD-L1 pathway in hepatocellular carcinoma." Journal of Oncology, 2022: 6988923. DOI: https://doi.org/10.1155/2022/6988923.
Wang, M., J. Zhang, L. Tong, X. Ma and X. Qiu, (2015). "MiR-195 is a key negative regulator of hepatocellular carcinoma metastasis by targeting FGF2 and VEGFA." International Journal of Clinical and Experimental Pathology, 8(11): 14110. PMID: 26823724.
Wang, Y., L. Yang, T. Chen, X. Liu, Y. Guo, Q. Zhu, X. Tong, W. Yang, Q. Xu and D. Huang, (2019a). "A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis." Molecular Cancer, 18(1): 1-16. DOI: https://doi.org/10.1186/s12943-019-0957-7.
Wang, S., M. Xu, Z. Sun, X. Yu, Y. Deng and H. Chang, (2019b). "LINC01018 confers a novel tumor suppressor role in hepatocellular carcinoma through sponging microRNA-182-5p." American Journal of Physiology-Gastrointestinal and Liver Physiology, 317(2): G116-G126. DOI: https://doi.org/10.1152/ajpgi.00005.2019.
Wang, Y. and K. Cao, (2021a). "KDM1A promotes immunosuppression in hepatocellular carcinoma by regulating PD-L1 through demethylating MEF2D." Journal of Immunology Research, 2021. DOI: https://doi.org/10.1155/2021/9965099.
Wang, J., J. Li, G. Tang, Y. Tian, S. Su and Y. Li (2021b). "Clinical outcomes and influencing factors of PD‑1/PD‑L1 in hepatocellular carcinoma." Oncology Letters, 21(4): 1-1. DOI: https://doi.org/10.3892/ol.2021.12540.
White, D. L., F. Kanwal and H. B. El–Serag, (2012). "Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review." Clinical Gastroenterology and Hepatology 10(12): 1342-1359. e1342. DOI: https://doi.org/10.1016/j.cgh.2012.10.001.
Wong, C. M., L. Wei, S. L. K. Au, D. N. Y. Fan, Y. Zhou, F. H. C. Tsang, C. T. Law, J. M. F. Lee, X. He and J. Shi, (2015). "MiR-200b/200c/429 subfamily negatively regulates Rho/ROCK signaling pathway to suppress hepatocellular carcinoma metastasis." Oncotarget, 6(15): 13658–13670. DOI: https://doi.org/10.18632/oncotarget.3700.
Xin, R., W. Li, Z. Hu, Z. Wu and W. Sun, (2020). "MiR-329-3p inhibits hepatocellular carcinoma cell proliferation and migration through USP22-Wnt/β-Catenin pathway." European Review for Medical and Pharmacological Sciences, 24(19): 9932-9939. DOI: https://doi.org/10.26355/eurrev_202010_23204.
Xu, T., Y. Zhu, Y. Xiong, Y. Y. Ge, J. P. Yun and S. M. Zhuang, (2009). "MicroRNA‐195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells." Hepatology, 50(1): 113-121. DOI: https://doi.org/10.1002/hep.22919.
Xu, W., K. Li, C. Song, X. Wang, Y. Li, B. Xu, X. Liang, W. Deng, J. Wang and J. Liu, (2020). "Knockdown of lncRNA LINC01234 suppresses the tumorigenesis of liver cancer via sponging miR-513a-5p." Frontiers in Oncology, 10: 571565. DOI: https://doi.org/10.3389/fonc.2020.571565.
Xu, X., Y. Tao, L. Shan, R. Chen, H. Jiang, Z. Qian, F. Cai, L. Ma and Y. Yu, (2018). "The role of microRNAs in hepatocellular carcinoma." Journal of Cancer, 9(19): 3557-3569. DOI: https://doi.org/10.7150/jca.26350.
Yan, Y. H., L. T. Zheng, Q. Du, X. Cui, K. Dong, Y. R. Guo and D. A. Geller, (2021). "Interferon regulatory factor 1 (IRF-1) downregulates Checkpoint kinase 1 (CHK1) through miR-195 to upregulate apoptosis and PD-L1 expression in hepatocellular carcinoma (HCC) cells." British Journal of Cancer, 125(1): 101-111. DOI: https://doi.org/10.1038/s41416-021-01337-6.
Yang, H., W. Zheng, X. Shuai, R.-M. Chang, L. Yu, F. Fang and L. Y. Yang, (2015). "MicroRNA-424 inhibits Akt3/E2F3 axis and tumor growth in hepatocellular carcinoma." Oncotarget, 6(29): 27736-50. DOI: https://doi.org/10.18632/oncotarget.4811.
Yao, H., X. Liu, S. Chen, W. Xia and X. Chen, (2015). "Decreased expression of serum miR-424 correlates with poor prognosis of patients with hepatocellular carcinoma." International Journal of Clinical and Experimental Pathology, 8(11): 14830-5. PMID: 26823812.
Yi, M., M. Niu, L. Xu, S. Luo and K. Wu, (2021). "Regulation of PD-L1 expression in the tumor microenvironment." Journal of Hematology and Oncology, 14(1): 1-13. DOI: https://doi.org/10.1186/s13045-020-01027-5.
Yu, S., L. Jing, X. R. Yin, M. C. Wang, Y. M. Chen, Y. Guo, K. J. Nan and L. L. Han, (2017). "MiR-195 suppresses the metastasis and epithelial–mesenchymal transition of hepatocellular carcinoma by inhibiting YAP." Oncotarget, 8(59): 99757-71. DOI: https://doi.org/10.18632/oncotarget.20909.
Zeng, C., S. Ye, Y. Chen, Q. Zhang, Y. Luo, L. Gai and B. Luo, (2021). "HOXA-AS3 promotes proliferation and migration of hepatocellular carcinoma cells via the miR-455-5p/PD-L1 axis." Journal of Immunology Research, 2021: 9289719. DOI: https://doi.org/10.1155/2021/9289719.
Zhang, H., Z. Zhang, L. Gao, Z. Qiao, M. Yu, B. Yu and T. Yang, (2019). "miR-1-3p suppresses proliferation of hepatocellular carcinoma through targeting SOX9." Oncotargets and Therapy, 12: 2149-57. DOI: https://doi.org/10.2147/OTT.S197326
Zhang, J., X. Zhao, X. Ma, Z. Yuan and M. Hu (2020). "KCNQ1OT1 contributes to sorafenib resistance and programmed death‑ligand‑1‑mediated immune escape via sponging miR‑506 in hepatocellular carcinoma cells." International Journal of Molecular Medicine, 46(5): 1794-1804. DOI: https://doi.org/10.3892/ijmm.2020.4710
Zhang, X. X., B. L. Pan, J. C. Qiu, X. L. Ke, S. L. Shen, X. Q. Wang and N. H. Tang, (2022). "lncRNA MIAT targets miR-411-5p/STAT3/PD-L1 axis mediating hepatocellular carcinoma immune response." International Journal of Experimental Pathology, 103(3): 102-111. DOI: https://doi.org/10.1111/iep.12440.
Zhao, L., H. Yu, S. Yi, X. Peng, P. Su, Z. Xiao, R. Liu, A. Tang, X. Li and F. Liu, (2016). "The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer." Oncotarget, 7(29): 45370-84. DOI: https://doi.org/10.18632/oncotarget.9659.
Zhao, Y., C. Zhu, Q. Chang, P. Peng, J. Yang, C. Liu, Y. Liu, X. Chen, Y. Liu and R. Cheng, (2020). "MiR-424-5p regulates cell cycle and inhibits proliferation of hepatocellular carcinoma cells by targeting E2F7." PLoS One, 15(11): e0242179. DOI: https://doi.org/10.1371/journal.pone.0242179.
Zhu, B., J. J. Chen, Y. Feng, J. L. Yang, H. Huang, W. Y. Chung, Y. L. Hu and W. J. Xue, (2021). "DNMT1-induced miR-378a-3p silencing promotes angiogenesis via the NF-κB signaling pathway by targeting TRAF1 in hepatocellular carcinoma." Journal of Experimental & Clinical Cancer Research, 40(1): 352(1-19). DOI: https://doi.org/10.1186/s13046-021-02110-6.
- Abstract Viewed: 139 times
- PDF Downloaded: 93 times